Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019;70(3):531–44.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, et al. The natural history of Advanced Fibrosis due to nonalcoholic steatohepatitis: data from the Simtuzumab trials. Hepatology. 2019;70(6):1913–27.
Article CAS PubMed Google Scholar
Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–705.
Article CAS PubMed Google Scholar
Simon TG, Roelstraete B, Khalili H, Hagstrom H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375–82.
Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clinic Proceedings. 2015;90(9):1233-46.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of Liver Diseases. Hepatology. 2018;67(1):328–57.
Torres DM, Williams CD, HarrisonO SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2012;10(8):837–58.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-+.
Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106(3):460–8; quiz 9.
Article PubMed PubMed Central Google Scholar
Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–55.
Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a Nexus of metabolic and hepatic Diseases. Cell Metabolism. 2018;27(1):22–41.
Article CAS PubMed Google Scholar
Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nature Reviews Gastroenterology & Hepatology. 2018;15(2):111–28.
Eslam M, Sanyal AJ, George J, Int Consensus P. MAFLD: A Consensus-Driven proposed nomenclature for metabolic Associated fatty liver disease. Gastroenterology. 2020;158(7):1999-+.
Article CAS PubMed Google Scholar
Chitturi S, Wong VW-S, Chan W-K, Wong GL-H, Wong SK-H, Sollano J, et al. The Asia-Pacific Working Party on non-alcoholic fatty liver Disease guidelines 2017Part 2: management and special groups. Journal of Gastroenterology and Hepatology. 2018;33(1):86–98.
Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. American Journal of Physiology-Endocrinology and Metabolism. 2005;288(2):E462-E8.
Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and Meta-analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology. 2015;13(4):643-+.
Loomba R, Adams LA. The 20% rule of NASH Progression: the natural history of Advanced Fibrosis and Cirrhosis caused by NASH. Hepatology. 2019;70(6):1885–8.
Zhou Y-Y, Zhou X-D, Wu S-J, Fan D-H, Van Poucke S, Chen Y-P, et al. Nonalcoholic fatty liver Disease contributes to subclinical atherosclerosis: a systematic review and Meta-analysis. Hepatology Communications. 2018;2(4):376–92.
Article CAS PubMed PubMed Central Google Scholar
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but No other histologic features, is Associated with Long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-+.
Xu L, Ma H, Miao M, Li Y. Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: a prospective case-control study. J Hepatol. 2012;57(5):1153–4.
Article CAS PubMed Google Scholar
Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. Plos One. 2010;5(7).
Ma H, Xu C, Xu L, Yu C, Mao M, Li Y. Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly chinese population. Bmc Gastroenterology. 2013;13.
Xu C, Wan X, Xu L, Miao M, Li Y, Yu C. Xanthine Oxidase promotes hyperuricemia and nonalcoholic fatty liver disease in patients and mice. Gastroenterology. 2015;148(4):S1053-S.
Wehmeyer MH, Zyriax B-C, Jagemann B, Roth E, Windler E, Zur Wiesch JS, et al. Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. Medicine. 2016;95(23).
Kwok R, Choi KC, Wong GL-H, Zhang Y, Chan HL-Y, Luk AO-Y, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65(8):1359–68.
Article CAS PubMed Google Scholar
Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nature Reviews Gastroenterology & Hepatology. 2016;13(7):412–25.
Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222-+.
Article CAS PubMed PubMed Central Google Scholar
Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Cancer focus lipid metabolism and cancer. Journal of Experimental Medicine. 2021;218(1).
Hirsova P, Ibrabim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res. 2016;57(10):1758–70.
Article CAS PubMed PubMed Central Google Scholar
Ralston JC, Lyons CL, Kennedy EB, Kirwan AM, Roche HM. Fatty acids and NLRP3 inflammasome-mediated inflammation in metabolic tissues. Annu Rev Nutr. 2017;37:77–102.
Article CAS PubMed Google Scholar
Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(5):1389–97.
Article CAS PubMed Google Scholar
Fu S, Watkins SM, Hotamisligil GS. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metabolism. 2012;15(5):623–34.
Article CAS PubMed Google Scholar
Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510(7503):84–91.
Article CAS PubMed PubMed Central Google Scholar
Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation. 2006;116(11):3015–25.
Article CAS PubMed PubMed Central Google Scholar
Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM, et al. Obesity-Induced CerS6-Dependent C-16:0 Ceramide Production promotes weight gain and glucose intolerance. Cell Metabolism. 2014;20(4):678–86.
Article CAS PubMed Google Scholar
Xia JY, Holland WL, Kusminski CM, Sun K, Sharma AX, Pearson MJ, et al. Targeted induction of Ceramide Degradation leads to Improved systemic metabolism and reduced hepatic steatosis. Cell Metabolism. 2015;22(2):266–78.
Article CAS PubMed PubMed Central Google Scholar
GarciaRuiz C, Colell A, Mari M, Morales A, FernandezCheca JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species - role of mitochondrial glutathione. Journal of Biological Chemistry. 1997;272(17):11369–77.
Article CAS PubMed Google Scholar
Martinez L, Torres S, Baulies A, Alarcon-Vila C, Elena M, Fabrias G, et al. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis. Oncotarget. 2015;6(39):41479–96.
Article PubMed PubMed Central Google Scholar
Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, et
Comments (0)